Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | SVP, Chief Accounting Officer | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,512 |
Ending reported balance
After 2026-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-05 · Tax withholding · Disposed 1,436 · Balance 7,799 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Row 2 · 2026-03-09 · Sale · Disposed 1,287 · Balance 6,512 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2022 Filed May 11, 2022 21:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 11 | $150.49 | $1,655.39 |
DisclosureSEC source: 0001765581-22-000047 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,229 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,056 | $148.93 | $157,268.07 |
DisclosureSEC source: 0001765581-22-000047 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,240 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.92 to $149.91 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000013 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,296 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| November 30, 2021 Filed Jan 14, 2022 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | OtherOrdinary Shares | 63 | $101.46 | $6,392.26 |
DisclosureSEC source: 0001765581-22-000007 · edgardoc.xml · nonDerivative · entry 3 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 F2 · kind: Shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021. This transaction is exempt pursuant to Rule 16b-3(c). Read SEC document |
| September 03, 2021 Filed Jan 14, 2022 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 143 | $136.48 | $19,516.64 |
DisclosureSEC source: 0001765581-22-000007 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,745 Read SEC document |
| September 03, 2021 Filed Jan 14, 2022 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 147 | $136.62 | $20,083.14 |
DisclosureSEC source: 0001765581-22-000007 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,888 F1 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. This acquisition is exempt pursuant to Rule 16b-3(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 157 | $147.96 | $23,229.72 |
DisclosureSEC source: 0001765581-21-000100 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 961 | $161.50 | $155,201.50 |
DisclosureSEC source: 0001765581-21-000044 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,045 Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,089 | $161.61 | $175,988.06 |
DisclosureSEC source: 0001765581-21-000044 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.6026 to $161.6082. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000014 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 62 | $152.55 | $9,457.97 |
DisclosureSEC source: 0001765581-20-000129 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · balance_after: Includes 62 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 142 | $123.80 | $17,579.60 |
DisclosureSEC source: 0001765581-20-000091 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 23:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 158 | $125.87 | $19,887.49 |
DisclosureSEC source: 0001765581-20-000089 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,342 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| June 05, 2020 Filed Jun 5, 2020 20:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 138 | $124.00 | $17,112.00 |
DisclosureSEC source: 0001765581-20-000059 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 138 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 22:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 600 | $102.17 | $61,302.00 |
DisclosureSEC source: 0001765581-20-000047 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 568 | $111.45 | $63,302.52 |
DisclosureSEC source: 0001765581-20-000042 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $111.4401 to $111.4550. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 232 | $119.17 | $27,648.18 |
DisclosureSEC source: 0001765581-20-000042 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,668 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 00:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 253 | $118.67 | $30,023.51 |
DisclosureSEC source: 0001765581-20-000028 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 247 | $119.75 | $29,578.23 |
DisclosureSEC source: 0001765581-20-000028 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,153 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000016 · edgardoc.xml · derivative · entry 2 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Ordinary Shares · 6,500 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000016 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $123.36 | $0.00 |
DisclosureSEC source: 0001765581-19-000100 · edgardoc.xml · derivative · entry 4 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313 Underlying: Ordinary Shares · 1,667 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 82 | $149.84 | $12,286.88 |
DisclosureSEC source: 0001765581-19-000100 · edgardoc.xml · nonDerivative · entry 3 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,667 | $148.89 | $248,197.96 |
DisclosureSEC source: 0001765581-19-000100 · edgardoc.xml · nonDerivative · entry 2 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,882 Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 1,667 | $123.36 | $205,641.12 |
DisclosureSEC source: 0001765581-19-000100 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 82 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000084 · edgardoc.xml · nonDerivative · entry 1 Carr Patricia · CIK 0001784606 · VP, Finance& PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of August 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.